India: Panacea gets license to Manufacture Sputnik V vaccine

The license is a necessary condition for using Sputnik V produced by Panacea Biotec in India.

57
Medicine Medical
Picture: Pixabay

Last Updated on July 7, 2021 by The Health Master

Panacea Biotec announced receipt of manufacturing license from Drugs Controller General (India) (DCGI) for Sputnik V vaccine against C-19 pursuant to its collaboration with Russian Direct Investment Fund (Russia’s sovereign wealth fund).

The license is a necessary condition for using Sputnik V produced by Panacea Biotec in India.

A company statement informed, “The batches produced at Panacea Biotec’s facilities at Baddi, Himachal Pradesh were earlier shipped to the Gamaleya Center in Russia for quality control.

DCGI CDSCO

The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory (CDL), Kasauli, Himachal Pradesh in India.”

Sputnik V was registered in India under the emergency use authorisation procedure on April 12, 2021, and vaccination against C-19 with the Russian vaccine started on May 14, 2021.

Sputnik V has been registered in 67 countries globally. The vaccine is based on a platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination.

USFDA approves Abbott’s Stent to treat high bleeding risk patients

Zydus Cadila gets USFDA nod for drug to treat HIV infection

Alembic gets USFDA nod for Nitrofurantoin Capsules USP

Axio Biosolution gets USFDA nod for Patch for bleeding control

Glenmark gets USFDA nod for generic Lung cancer drug

USFDA okays Tocilizumab for treatment of Covid-19

Procedure to obtain License to Manufacture drugs for testing and analysis…

9 arrested over supplying spurious drugs remanded in Police custody

Oral dose for COVID from Indian Drug maker soon

This Hospital to offer free plastic surgery

Neurological disorder: Treat Kids without delay: Doctors

Germany recommends mixing of these vaccines

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner